The diabetes care devices market was worth over $19bn in 2020, and is expected to grow to $25.4bn by 2025 with a CAGR of 6.5%, driven by the strong performance of the continuous glucose monitors (CGM) market, according to GlobalData, a leading data and analytics company.
GlobalData anticipates the continued growth of the CGM and closed-loop pumps market will be over 20% in 2021, due to increasing awareness from patients and diabetic care providers. The technological improvement of CGM has made the devices increasingly reliable, more user-friendly, and efficacious in terms of improving glycemic control. Additionally, CGM usage will expand from type 1 diabetes (TD1) and type 2 diabetes (TD2) on intensive insulin therapy to broader populations including non-intensive TD2, pre-diabetes, pregnancy, and the hospital market.
Tina Deng, MSc, Principal Medical Devices Analyst at GlobalData, comments: “The collaborations between insulin delivery and CGM manufacturers are closer in 2021 due to the CGM-led diabetes management revolution. For example, to compete with MiniMed 770G, Abbott is working with Insulet to develop a platform to integrate its CGM sensing technology with Insulet’s patch pump, Omnipod.
“The platform allows glucose data from a CGM sensor to send to Omnipod and automatically adjust insulin delivery to a patient. The market disruptor, Bigfoot Biomedical, recently received FDA 510(k) clearance for its Bigfoot Unity. The system features connected smart pen caps that work in conjunction with FreeStyle Libre 2 to recommend insulin doses for patients using multiple daily injection therapy. These devices are expected to take a significant share from the traditional glucose meters and delivery systems.”
Additionally, digital technology and new models of diabetes care have been rapidly deployed to meet the challenges of the COVID-19 pandemic, such as not being able to visit their doctor on a regular basis. Dexcom’s CLARITY clinic software provides healthcare professionals with a web-based portal to view their patients’ CGM summary data. Since the software was deployed, clinical usage of CLARITY has increased greatly to serve patients with diabetes during lockdown. As the software largely simplifies the diabetic management process for patients and clinicians, it will be continually used post the pandemic.